---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Indication questions"
description: "Indication questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Trelegy Ellipta approved for in COPD? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease: Indication questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)

Indication questions that apply to every indication of Trelegy Ellipta are on [Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Indication](https://www.evicenter.com/medical-information/trelegy-ellipta/indication).

## Indication

<a id="trelegy-indication"></a>

### What is Trelegy Ellipta approved for in COPD?

> “COPD: TRELEGY 100/62.5/25 is for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=COPD%3A%20TRELEGY%20100%2F62.5%2F25%20is%20for,chronic%20obstructive%20pulmonary%20disease%20%28COPD%29.)

> “TRELEGY ELLIPTA is indicated for the maintenance treatment of patients with chronic 
> obstructive pulmonary disease (COPD).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 2, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=2)

> “Limitations of Use: TRELEGY is NOT for the relief of acute bronchospasm.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Limitations%20of%20Use%3A%20TRELEGY%20is%20NOT%20for%20the%20relief%20of%20acute%20bronchospasm.)

Note: The label also covers maintenance treatment of asthma in patients aged 18 years and older.

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)
- [Clinical trials](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease/guidelines)
